The final, formatted version of the article will be published soon.
EDITORIAL article
Front. Med.
Sec. Nephrology
Volume 12 - 2025 |
doi: 10.3389/fmed.2025.1559841
This article is part of the Research Topic Pathogenesis and Clinical Treatment of Diabetic Nephropathy View all 5 articles
Editorial: Pathogenesis and Clinical Treatment of Diabetic Nephropathy
Provisionally accepted- 1 School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, SAR China
- 2 Department of Nephrology, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, China
- 3 Division of Nephrology, Baylor College of medicine, Houston, United States
Diabetic Nephropathy (DN) is a severe complication of diabetes mellitus, representing a significant global health burden. It is estimated that there are 823 million diabetes patients in 2022, with the number projected to exceed 1.3 billion by 2050 (1,2). The worldwide study indicates that the prevalence of end-stage renal disease (ESRD) is 29% among individuals with diabetes (3).Recent research has provided insights into different aspects of the pathogenesis and clinical treatment of DN. The editorial aims to synthesize insights from four pivotal studies that collectively deepen our understanding of the pathogenesis and clinical management of DN (4)(5)(6)(7). These studies address key areas in diabetic nephropathy, including recent advances in pharmacological management, the association between body weight fluctuations and fracture risk, the evaluation of clinical efficacy and safety in peritoneal dialysis and hemodialysis patients, and the role of protein methylation in DN pathogenesis. Together, they offer a multifaceted perspective on the challenges and opportunities in managing DN.
Keywords: diabetic nephropathy, epigentics, Pharmacological Agents, Diabetic kidney disease, Fracture
Received: 13 Jan 2025; Accepted: 20 Jan 2025.
Copyright: © 2025 Xu, Qiang, Hu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhaoyong Hu, Division of Nephrology, Baylor College of medicine, Houston, United States
Haiyong Chen, School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong, SAR China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.